HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies

Current Opinion in Rheumatology

Volumn 8, Issue 6, 1996, Pages 528-538

  Hoffman, Eric P ^a   Clemens, Paula R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DYSTROPHIN; LAMININ;

BECKER MUSCULAR DYSTROPHY; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DUCHENNE MUSCULAR DYSTROPHY; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HUMAN; MUSCLE BIOPSY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKAGE;

CHILD; CHILD, PRESCHOOL; CREATINE KINASE; CYTOSKELETAL PROTEINS; CYTOSKELETON; DYSTROPHIN; FEMALE; GENETIC SCREENING; HUMANS; INFANT; INFANT, NEWBORN; LAMININ; MALE; MUSCULAR DYSTROPHIES;

EID: 0030499025     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199611000-00006     Document Type: Review

References (42)

1. Hoffman EP, Brown RH, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1967, 51:919-928.
2. Menke A, Jockusch H: Extent of shock-induced membrane leakage in human and mouse myotubes depends on dystrophin. J Cell Sci 1995, 108:727-733. One of several recent papers directly addressing possible functions of dystrophin. The results support a membrane-stabilizing role for dystrophin.
3. Fabbrizio E, Bonet-Kerrache A, Limas F, Hugon G, Mornet D: Dystrophin, the protein that promotes membrane resistance. Biochem Biophys Commun 1995, 213:295-301.
4. Azofeifa J, Voit T, Hubner C, Cremer M: X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. Hum Genet 1995, 96:167-176.
5. Naylor EW, Hoffman EP, Paulus-Thomas J, et al.: Neonatal screening for Duchenne/Becker muscular dystrophy: reconsideration based on molecular diagnosis and potential therapeutics. Screening 1992, 1:99-113.
6. Ueda H, Kobayashi T, Mitsui K, Tsurugi K, Tsukahara S, Ohno S: Dystrophin localization at presynapse in rat retina revealed by immunoelectron microscopy. Invest Ophthalmol Vis Sci 1995, 36:2318-2322.
7. Mehler MF, Haas KZ, Kessler JA, Stanton PK: Enhanced sensitivity of hippocampal pyramidal neurons from mdx mice to hypoxia-induced loss of synaptic transmission. Proc Natl Acad Sci U S A 1992, 89:2461-2465.
8. Vaillend C, Rendon A, Misslin R, Ungerer A: Influence of dystrophin-gene mutation on mdx mouse behavior: I: retention deficits at long delays in spontaneous alternation and bar pressing tasks. Behav Genet 1995, 25:569-579.
9. Dubowitz V: Intellectual impairment in muscular dystrophy. Arch Dis Child 1965, 40:296-305.
10. Hoffman EP, Kunkel LM, Angelini C, et al.: Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 1989, 39:1011-1017.
11. Gospe SM, Lazaro RP, Lava NS, Grootscholten PM, Scott MO, Fischbeck KH: Familial X-linked myalgia and cramps. Neurology 1989, 39:1277-1280.
12. Sunohara N, Arahata K, Hoffman EP, et al.: Quadriceps myopathy: forme fruste of Becker muscular dystrophy. Ann Neurol 1990, 28:634-639.
13. Gold R, Kress W, Meurers B, Meng G, Reichmann H, Muller CR: Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve 1992, 15:214-218.
14. Comi GP, Prelle A, Bresolin N, et al.: Clinical variability in Becker muscular dystrophy: genetic, biochemical, and immunohistochemical correlates. Brain 1994, 117:1-14.
15. Doriguzzi C, Palmucci L, Mongini T, Chiado-Piat L, Restagno G, Ferrone M: Exercise intolerance and recurrent myoglobinuria as the only expression of Xp21 Becker type muscular dystrophy. J Neurol 1993, 240:269-271.
16. Palmucci L, Doriguzzi C, Mongini T, Restagno G, Chiado-Piat L, Maniscalco M: Unusual expression and very mild course of Xp21 muscular dystrophy (Becker type) in a 60-year-old man with 26 percent deletion of the dystrophin gene. Neurology 1994, 44:541-543.
17. Palmucci L, Doriguzzi C, Mongini T, et al.: Dilating cardiomyopathy as the expression of Xp21 Becker type muscular dystrophy. J Neurol Sci 1992, 111:218-221.
18. Morrone A, Zammarchi E, Hoop RC, Donati A, Servidei S, Hoffman EP: Asymptomatic dystrophinopathy. Am J Med Genet 1996, in press. This paper describes an extended family segregating a deletion mutation of the dystrophin gene, yet showing no clinical symptoms of a dystrophinopathy. The family was identified based on elevated serum transaminases during medical examination.
19. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM: Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991, 49:54-67.
20. Arikawa E, Hoffman EP, Kaido M, et al.: The frequency of patients having dystrophin abnormalities in a limb-girdle patient population. Neurology 1991, 41:1491-1496.
21. Minetti C, Chang HW, Medori R, et al.: Dystrophin deficiency in young girls with sporadic myopathy and normal karyotype. Neurology 1991, 41:1288-1291.
22. Hoffman EP, Arahata K, Minetti C, et al.: Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992, 42:967-975.
23. Malapert D, Recan D, Leturcq F, Degos JD, Gherardi RK: Sporadic lower limb hypertrophy and exercise induced myalgia in a woman with dystrophin gene deletion. J Neurol Neurosurg Psychiatry 1995, 59:552-554.
24. Pegoraro E, Schimke RN, Garcia C, et al.: Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin competent myonuclei. Neurology 1995, 45:677-690. A complex study examining female patients heterozygous for dystrophin gene mutations to study the plasticity of muscle in pathologic situations.
25. Pegoraro E, Schimke RN, Arahata K, et al.: Dystrophinopathy in females: paternal inheritance and genetic counseling. Am J Hum Genet 1994, 54:989-1003.
26. Hoffman EP, Pegoraro E, Scacheri P, Bums RG, Taber JW, Weiss L, Spiro A, Blattner P: Genetic counseling of isolated carriers of Duchenne muscular dystrophy. Am J Med Genet 1996, 63:573-580.
27. Roberds SL, Leturcq F, Allamand V, et al.: Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994, 78:625-633.
28. Piccolo F, Roberds SL, Jeanpierre M, et al.: Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet 1995, 10:243-245. A molecular and phenotypic study of a series of patients showing α-sarcoglycan gene mutations. Patients showed variable clinical severity, from childhood onset to adult onset.
29. Ljunggren A, Duggan O, McNally E, et al.: Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. Ann Neurol 1995, 38:367-372.
30. Bonnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, McNally EM, Duggan D, Angelini C, Hoffman EP, Ozawa E, Kunkel LM: Beta-sarcogylcan (A3B) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet 1995, 11:266-273. One of a pair of papers (see Lim et al., Nat Genet 1995, 11:257-265) describing the first patients with mutations of the β-sarcoglycan gene. These patients showed a muscular dystrophy similar to Duchenne muscular dystrophy and showed a secondary deficiency of the other sarcoglycan proteins.
31. Lim LE, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V, Meyer J, Richard I, Moomaw C, Slaughter C, et al.: β-Sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet 1995, 11:257-265. One of a pair of papers (see Bonnemann et al., Nat Genet 1995, 11:266-273) showing patients with β-sarcoglycan mutations.
32. Noguchi S, McNally EM, Ben Othmane K, et al.: Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995, 270:819-822. γ-Sarcoglycan is found to be the cause of the autosomal recessive muscular dystrophy prevalent in Tunisia.
33. Bueno MR, Moreira ES, Vainzof M, Chamberlain J, Marie SK, Pereira L, Akiyama J, Roberds SL, Campbell KP, Zatz M: A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Hum Mol Genet 1995, 4:1163-1167.
34. Passos-Bueno MR, Moreira ES, Vainzof M, Marie SK, Zatz M: Linkage analysis in autosomal recessive limb-girdle muscular dystrophy (AR LGMD) maps a sixth form to 5q33-34 (LGMD 2F) and indicates that there is at least one more subtype of AR LGMD. Hum Mol Genet 1996, 5:815-820.
35. Nigro V, Moreira ES, Piluso G, Vainzof M, Belsito A, Politano L, Puca AA, Passos-Bueno MR, Zatz M: Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 1996, 13:195-198. This paper shows that all families in Brazil mapped to the 5q33 limb-girdle dystrophy locus share the same mutation of the δ-sarcoglycan gene.
36. McNally EM, Duggan DJ, Gorospe JR, Bonnemann C, Fanin M, Pegoraro, E, Lidov HGW, Nogushi S, Ozawa E, Finkel RS, et al.: Mutations that disrupt the carboxyl-terminus of γ-sarcoglycan cause muscular dystrophy. Hum Mol Genet, 1996, 5:1841-1847. A series of patients with γ-sarcoglycan mutations are studied.
37. Tome FM, Evangelista T, Leclerc A, et al.: Congenital muscular dystrophy with merosin deficiency. Comptes Rendus Acad Sci 1994, 317:351-357.
38. Sewry CA, Philpot J, Mahony D, Wilson LA, Muntoni F, Dubowitz V: Expression of laminin subunits in congenital muscular dystrophy. Neuromuscul Disord 1995, 5:307-316. A study of merosin-deficient congenital muscular dystrophy. The authors found MRI abnormalities in all patients studied, despite normal cognitive function.
39. Pegoraro E, Mancias P, Swerdlow SH, Raikow RB, Garcia C, Marks H, Crawford T, Carver V, DiCianno B, Hoffman EP: Congenital muscular dystrophy (CMD) with primary laminin α2 deficiency presenting as inflammatory myopathy. Ann Neurol 1996, 46:810-814. The authors describe a series of merosin-deficient congenital muscular dystrophy patients and show that a subset had been given an infantile polymyositis diagnosis due to inflammation in the biopsy specimen. Clear loss-of-function mutations of the merosin gene were identified in one patient with dramatic inflammation in his biopsy specimen.
40. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, Tome FMS, Schwartz K, Fardeau M, Tryggvason K, Guicheney P: Mutations in the laminin α2-chain (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 1995, 11:216-218. The first report of mutations in the large and complex merosin gene.
41. Connolly AM, Pestronk A, Planer GJ, et al.: Congenital muscular dystrophy syndromes distinguished by alkaline and acid phosphatase, merosin, and dystrophin staining. Neurology 1996, 46:810-814.
42. Voit T, Fardeau M, Tome FM: Prenatal detection of merosin expression in human placenta. Neuropediatrics 1994, 25:332-333.